Inactive Instrument

GENFIT Stock Euronext Paris

Equities

FR0004163111

Biotechnology & Medical Research

End-of-day quote Euronext Paris
- EUR - Intraday chart for GENFIT

Financials

Sales 2024 * 82.45M 88.31M 121M Sales 2025 * 48.61M 52.07M 71.21M Capitalization 173M 185M 253M
Net income 2024 * 19M 20.35M 27.83M Net income 2025 * -21M -22.49M -30.76M EV / Sales 2024 * 1.99 x
Net cash position 2024 * 8.71M 9.33M 12.76M Net cash position 2025 * 44.9M 48.09M 65.77M EV / Sales 2025 * 2.63 x
P/E ratio 2024 *
13.6 x
P/E ratio 2025 *
-36.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.86%
More Fundamentals * Assessed data
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
HC Wainwright Raises Genfit SA Price Target to $13 From $11, Maintains Buy Rating MT
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis CI
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment MT
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug RE
US FDA approves Genfit and Ipsen's liver disease drug RE
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
More news
Managers TitleAgeSince
Chief Executive Officer 56 18-04-30
Founder 68 99-08-31
Director of Finance/CFO 50 21-04-21
Members of the board TitleAgeSince
Director/Board Member 67 21-03-03
Founder 68 99-08-31
Founder 52 99-09-14
More insiders
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Calendar
More about the company